{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091201","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.390262+00:00","generated_at":"2026-05-31T12:21:13.985309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed","bullets":["Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.","Cash, cash equivalents and marketable securities $1.0B at June 30 vs $1.2B at Dec 31, 2023.","BEAM-101 Phase 1/2 BEACON trial: >20 patients enrolled, 6 dosed; initial data submitted for ASH.","FDA cleared IND for BEAM-301 (GSDIa); patient dosing expected in early 2025.","First patient dosed in BEAM-302 Phase 1/2 trial (AATD); initial clinical data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091201","json":"https://secwatch.observer/filing/0000950170-24-091201.json","markdown":"https://secwatch.observer/filing/0000950170-24-091201.md","text":"https://secwatch.observer/filing/0000950170-24-091201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024091201/0000950170-24-091201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024091201/beam-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:21:13.985309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}